What type of study is this?

This is a RCT study (also classified as: Phase 2).

September 22, 2025JAMA Network OpenOpen Access

Efficacy and Safety of Ammoxetine in Major Depressive Disorder

View Full Paper

Ask AI

Bookmark

Authors

HSHe ShenChinese Academy of Medical Sciences & Peking Union Medical College JCJing ChenUniversity of Connecticut YXYU Xue-qinChongqing City Mental Health Center

Discussion

Member takes

Implication

Randomized clinical trial shows ammoxetine improves depression scores in adults with major depressive disorder, indicating it may be an effective treatment option.

Key Points

Ammoxetine at both 40 mg/d and 60 mg/d showed significant improvements in depression scores compared to placebo.
Montgomery-Åsberg Depression Rating Scale scores decreased by -16.7 and -16.6 for the respective doses, indicating efficacy.
The clinical trial involved 239 participants across various centers in China, measuring both efficacy and safety outcomes.
All doses of ammoxetine were well tolerated, with most adverse events reported as mild to moderate in severity.

Cite This Study

Shen et al. (2025) studied this question.

synapsesocial.com/papers/68d46fdc31b076d99fa6a4c8 https://doi.org/10.1001/jamanetworkopen.2025.32650

View Full Paper

Ask AI

Bookmark

Implication

Randomized clinical trial shows ammoxetine improves depression scores in adults with major depressive disorder, indicating it may be an effective treatment option.

Efficacy and Safety of Ammoxetine in Major Depressive Disorder

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and Safety of Ammoxetine in Major Depressive Disorder

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider